1092 results about "New medications" patented technology

The present invention provides methods for enhanced detection of biological response profiles. In particular, the methods of this invention allow for the detection of biological response patterns, such as gene expression patterns, in response to different drug treatments. The methods of the invention also allow the determination of a "consensus profile" which describes a particular class or type of biological response. In certain embodiments the consensus profile may describe the biological response of a particular group or class of drugs. In other embodiments, the consensus profile may describe an "ideal" biological response such as one associated with a desired therapeutic effect. The methods of the present invention also allow for the comparison of different biological responses. Thus, the methods of the invention may be used, e.g., to identify and/or study new drugs.

The invention relates to a method for establishing a Gadd45a knockout rabbit model by adopting a knockout technology and belongs to the technical field of biotechnology. The invention aims to establish a rabbit model by knocking out GADD45a gene by utilizing a Grispr/cas9 technology and to provide the method for establishing the Gadd45a knockout rabbit model by adopting the knockout technology andfor researching the influence of the gene on animal liver. The method provided by the invention comprises the following steps: establishing sgRNA; synthesizing double-stranded DNA; linearizing p UC-57 carrier; linking p UC-57 carrier with double-stranded DNA; converting; performing monoclonal picking and plasmid DNA extraction; identifying plasmid sequence; expressing plasmid with CAS9; and performing digestion linearization for in vitro transcription. Through related detection, the invention successfully acquires the Gadd45a knockout rabbit model; the model is established for simulating theclinic pathological processes of the liver diseases, such as, fatty liver, liver cirrhosis and liver cancer after giving the corresponding alcohol stimulation, is capable of effectively forecasting the clinic application effects of new vaccine, new drugs and new diagnostic reagents, and meanwhile, and is capable of greatly reducing the risk in researching and developing the new drugs; and a basismodel is supplied for the clinical research.

The invention relates to a preparation method and application of Exendin-4 biologically located and modified by Evans blue (Evans Blue) or derivatives of Evans blue. The product generated after the C terminal of Exendin-4 is specifically modified with Evans blue or derivatives of Evans blue has biological activity similar to Exendin-4 which is not modified but has longer in vivo half-life than the Exendin-4 which is not modified. Based on the significance of the Exendin-4 in treatment of diseases, the invention also discloses application of the Exendin-4 modified by Evans blue or derivatives of Evans blue in preparation of medicines for treating type-II diabetes and myocardial infarction. The Exendin-4 has the advantages of simplicity and convenience in preparation, obvious curative effect, long-lasting and stable drug effect, convenience in storage and the like and has significance in research and development of new drugs for promoting anti-diabetic and anti-infarction high-efficiency treatment.

The invention discloses a three dimensional tissue and organ culture model, a high throughput automatic stereo image analyzing platform thereof, and a method utilizing the provided platform to screen antitumor drugs. The platform can be applied to the culture system of three dimensional tissue and organ/organ-like substance, three dimensional scanning and sampling system, and high-volume data storage and computer analysis system. The provided platform can simultaneously process a large amount of clinical samples and screen a plurality of antitumor drugs, is capable of greatly reducing the cost and maximally reducing the detection time, thus is widely applied to the drug selection schemes and dosage optimization in clinic, novel drug development, and basic researches on interactions among tissue, organ, biological macromolecules, and other micromolecules.

A self-assembling peptide constituted by D-amino acid is named as d-RAD16 and has an amino acid sequence represented by SEQ ID NO.1 in a sequence list. Test shows that hydrogel formed by the self-assembling peptide can be used for preparing a moisture keeping and water locking agent, and has the function of stopping bleeding rapidly for wound, so that the hydrogel can be used for preparing a hemostatic drug suiting clinical application by adding a pharmaceutically acceptable carrier or excipient. Nanofiber scaffold formed by the self-assembling peptide supports the growth of various cells and can be used as the substrate material for 3D cell culture. The substrate material for 3D cell culture can simulate the in-vivo environment to support the 3D growth of cells in the substrate, thereby providing a cell 3D culture drug screening mode capable of simulating the in-vivo environment and improving the success rate for the development of new drugs.

The invention discloses a method for preparing rare ginsenoside by hydrolyzing ginsenoside with acidic amino acid. Panoxadiol saponins are converted to generate 20R-Rg3, 20S-Rg3, Rg5 and Rk1, and panaxatriol saponins are converted to generate Rg6, F4, Rk3 and Rh4. Compared with an existing preparation process, the hydrolysis capacity of acidic amino acid is more than 10 times of that of neutral amino acid and that of basic amino acid and can better meet requirements of industrial preparation of rare ginsenoside, the defects that the hydrolysis specifity of ginsenoside is poor, the yield is low, the corrosion is high, environment pollution is caused, multiple byproducts are produced and the like due to the fact that a large amount of strong acid and strong base are used are overcome, ginseng resources are fully used, rare ginsenoside is extracted and enriched to the largest extent, the purpose of simple, quick, environment-friendly and low-cost enrichment of rare ginsenoside is achieved, and the method guarantees industrial production and preparation of new medicines.

A method of performing interactive clinical trials for testing a new drug comprising performing a pre-clinical phase in which a computer model for pharmacokinetics and pharmacodynamics of the drug is created and adjusted based on in vitro studies and in vivo studies in animals. A phase I clinical research is performed in which a clinical trial on at least a single dose is performed in parallel with performing computer simulation studies using the computer model. The computer model is adjusted based on comparison of the results of the clinical research and the computer simulation. A maximal tolerated dose, minimum effective dose, and a recommended dose is determined based on the phase I clinical research in conjunction with the computer simulations. The drug is checked for cumulative effects and providing this information to the computer model. Multiple simulations are performed using the computer model with different doses and dosing intervals. An optimal protocol is determined for the most responsive patient populations and indications for a phase II clinical trial. Phase II clinical trial is performed where a number of small scale clinical trials are performed in parallel based on results of the above. The interim results are analyzed to choose the most promising regimens for continued clinical trials. Phase III clinical research is performed for chosen indications by chosen protocols. Phase IV studies are performed for post-marketing subpopulation analysis and long term product safety assessment.

The invention belongs to the field of new chemically synthesized drugs and medical preparations thereof, particularly discloses a thermal gel controlled-release injection of a platinum-containing antitumor drug and a preparation method of the thermal gel controlled-release injection. The thermal gel controlled-release injection consists of Pt(IV)-containing amphipathic segmented copolymer and a solvent, wherein the water system can generate phase transformation of thermal gelation with temperature rise to spontaneously form physical hydrogel; the bonded Pt(IV) complex is easily reduced into Pt(IV); the amphipathic segmented copolymer consists of a hydrophilic block and a hydrophobic block which can be degraded into polyester, wherein a functional group is connected at the terminal of the block copolymer. The controlled-release gel preparation disclosed by the invention can be used for prolonging the release period of the platinum antitumor drugs. By virtue of an injection way, the preparation is dosed in tumor, around tumor or in a postoperative tumor cavity; after the preparation is gelled in situ in the body, the bonded platinum drugs can be slowly released from the gel, so that the dosing frequency and the whole body toxic and side effects are lowered.

The invention belongs to the technical field of new drug synthesis, and in particular relates to an IDO inhibitor containing (E)-4-(beta-bromovinyl)phenoxy acyl structure, as well as a preparation method thereof. The preparation method comprises the following steps: solvent benzene, (E)-4-(beta-bromovinyl) phenol, carboxylic acid and p-dimethylaminopyridine are added to a flask respectively and magnetically stirred for 5 to 20 minutes at room temperature; then N, N'-dicyclohexylcarbodiimide is added and reacts for 2 to 24 hours at room temperature; after the reaction is completed, the solvent benzene is steamed off after decompression; residue is subjected to column chromatography separation and purification by taking ethyl acetate/petroleum ether as leacheate, and then a needed product can be obtained, wherein the molar ratio of the solvent benzene to the (E)-4-(beta-bromovinyl) phenol is 50-200:1; the molar ratio of the carboxylic acid to the (E)-4-(beta-bromovinyl) phenol is 1-1.5:1; the molar ratio of the p-dimethylaminopyridine to the (E)-4-(beta-bromovinyl) phenol is 0.1-1.5:1; and the molar ratio of the N, N'-dicyclohexylcarbodiimide to the (E)-4-(beta-bromovinyl) phenol is 1-1.2:1. The method takes the (E)-4-(beta-bromovinyl) phenol as a synthesis building block and obtains a series of the novel IDO inhibitors containing the (E)-4-(beta-bromovinyl)phenoxy acyl structure through esterification reaction, and the IDO inhibitors can be used for treating the diseases with the pathological features of IDO mediated tryptophan metabolic pathway.

A method and a system for virtual design and evaluation of pharmaceutical formulation are provided. The invention discloses the method and the system for virtual design and evaluation of pharmaceutical preparation prescriptions, and the system mainly comprises a pre-prescription research module, a pharmaceutical prescription design and optimization module, a pharmaceutical preparation process design and optimization module, and a pharmaceutical prescription in-vivo prediction and evaluation module. The method and the system for virtual design and evaluation of pharmaceutical formulation predict the whole process of pharmaceutical formulation from four aspects of pharmaceutical pre-formulation research, formulation design, preparation process design and pharmacokinetics prediction in vivo.Compare with a conventional empirical drug prescription screening and preparation method in a traditional laboratory, the method and the system can accelerate the development of drug product, do not consume any laboratory equipment, complete the virtual design and evaluation of drug formulation prescription through a computer platform, shorten the drug development cycle and save the development cost of new drugs.

The invention discloses a high performance capillary electrophoresis (HPCE) quick quantitative method for four active components of fraxin, esculin, fraxetin and aesculetin in cortex fraxini or extract thereof. By the method provided by the invention, four cortex fraxini coumarins are well separated and determined in 10min, and simultaneously all the components have good linear relations and highrecovery rates. The method provided by the invention has good relativity of determination results compared with a high performance liquid chromatography (HPLC) method, greatly shortens the analyzing time, obviously reduces environmental pollution, notably decreases the analyzing and operating cost, provides a quick efficient analyzing means for researching the distribution of the active components of cortex fraxini and the variation rule of content in different harvest phases, and also can be used for researching the inherent quality of the cortex fraxini extract and for referencing in development research of new drugs.

The invention provides a pharmaceutical preparation for treating skin diseases and a preparation method thereof. It is mainly prepared from the raw materials of S. Some or all of the Kochia scoparia medicinal materials are used in combination. Compared with the prior art, the formula provided by the present invention can be prepared into oral preparations or external preparations according to the conventional preparation process. Sexual skin diseases have a good curative effect, the total effective rate can reach more than 95%, and it is safe to use, has no toxic and side effects, and does not produce drug resistance. It is a safe, effective and quality-controllable treatment for itchy skin diseases. New medicine of traditional Chinese medicine.

Although the compatibility principle of monarch, minister, assistant and guide formed under the traditional Chinese medicine theory is ordered, the action mechanism and scientific essence of the medicine cannot be revealed from essence, and the clinical effective rate of the traditional Chinese medicine is low. Therefore, the invention provides a method for screening the traditional Chinese medicine composition with the network targeting effect from the molecular level, the correlation between the disease symptom and the traditional Chinese medicine symptom is established from the molecular level through gene data analysis and traditional Chinese medicine data analysis, so that a traditional Chinese medicine action network with clear targeting and clear mechanism is obtained, and finally a network targeting formula is formed. A new thought is provided for research and development and action mechanism research of new traditional Chinese medicines, and modernization and internationalization of traditional Chinese medicines are assisted.

The invention discloses a method for quantitatively evaluating medicament toxicity by using metabonomic technology, which is characterized by comprising the following steps: comprehensively and quantitatively measuring small molecule compounds in a biological sample by using the measuring technology based on mass spectrum, nuclear magnetic resonance and the like, then establishing a multi-dimensional spatial mathematical model by adopting a multi-variable data processing method, calculating a relative distance between an administration group and a control group and taking the relative distance as a quantitative index for evaluating the medicament toxicity so as to solve the difficult problem that the medicament toxicity evaluation lacks the quantitative evaluating index. Compared with the conventional toxicity evaluating method, the method has the advantages of wide application, sensitivity, simple and convenient sampling, no harm to the body, and capability of reflecting the toxicity function more comprehensively, and providing a comprehensive and reliable quantitative evaluating method for toxicity evaluation in new medicament research and development and pharmacologic research.

The screening system utilizes dynamic measurements of pathway activity to detect the activities of drugs within cellular pathways. The methods of the invention can be used to identify previously unknown drug activities and therapeutic uses, even for drugs that have been well characterized with standard biochemical assays. We demonstrated the utility of the invention by screening a portion of the known pharmacopeia. We identified dozens of drugs, previously or currently marked for a variety of indications, with surprising and previously-unsuspected activity against ‘hallmark’ cancer pathways. We also showed that over 20 of these drugs indeed have anti-proliferative activity in human tumor cells, underscoring the utility and predictability of the screening system. The methodology will extend the utility of the current pharmacopeia and provide the basis for de novo discovery of drugs with a broad range of therapeutic indications.

The invention provides a novel traditional Chinese medicinal compound Subing (quick effect heart rescue) spraying agent and its preparation method and belongs to the field of biomedicine, wherein the Subing (quick effect heart rescue) spraying agent has a good curative effect of resisting coronary angina pectoris. The problem of dissolving borneol with levant storax oil is solved by a new technology and a new method. The prescription is composed of styrax, borneol, a solubiliser, an absorption enhancer and a solvent. By the simple new technology of dissolution, homogenization and the like, borneol which is completely insoluble in water and levant storax oil which is not miscible with water phase are dissolved together in an oral water-soluble base so as to obtain an oral solution which is uniform and transparent without layers and suspension. The spraying agent or aerosol prepared in the invention can be quantitatively and directly sprayed into mouth or sprayed under tongue or directly sprayed into nasal cavity. In comparison with a solid preparation, the spraying agent prepared by styrax and borneol for oral administration has advantages of fast absorption and rapid effect, can perform a curative effect better and faster, is applicable to be taken by patients with angina pectoris during the acute phase. By the adoption of the preparation method provided by the invention, the effect onset time is greatly shortened within 60 seconds. The preparation method provides a good therapeutic novel medicine for currently high frequency and high occurrence of heart disease in our country.

CD44, the receptor for hyaluronic acid, has complex functions in cellular physiology, cell migration and tumour metastasis. The inventors have previously found that human CD44 receptor overexpression in mouse fibrosarcoma cells inhibits subcutaneous tumour growth in mice [Kogerman et al., Oncogene 1997; 15:1407-16; Kogerman et al., Clin Exp Metastasis 1998; 16:83-93]. Here it is demonstrated that a tumour growth inhibitory effect of CD44 is caused by block of angiogenesis. Furthermore, the inventors have found that soluble recombinant CD44 hyaluronic acid binding domain (CD44HABD) inhibits angiogenesis in vivo in cLick and mouse and thereby inhibits human tumour growth of various origins. The anti-angiogenic effect of CD44-HABD is independent of hyaluronic acid (HA) binding, since non-HA-binding mutants of CD44HABD still maintain anti-angiogenic properties. The invention discloses soluble CD44 recombinant proteins as a novel class of angiogenesis inhibitors based on targeting of vascular cell surface receptor. A method of block of angiogenesis and treatment of human tumours using recombinant CD44 proteins as well as their analogues is disclosed. As a further embodiment of the invention, methods for screening for new drug targets using CD44 recombinant proteins and their analogues is presented.

The invention relates to a phenothiazine compound and a preparation method thereof. The invention further relates the application of the phenothiazine compound in anti-cancer drug preparation and anti-cancer drugs using the compound as the effective component. The phenothiazine compound has the advantages that the compound with broad-spectrum anti-cancer effect is obtained by modifying phenothiazine ternary interlink parent nucleuses, synthesizing method is simple, and high yield is achieved; the phenothiazine compound has certain restraining effect on human breast cancer cells line MCF-7 and human hepatoma cell line Hep-G2, and a new thought is provided to new drugs satisfying clinic requirements.

The invention relates to a novel broad-spectrum anti-inflammation analgesic drug for curing various oral diseases. The invention discloses a main compound extracted from mangosteen:Garcinia mangostana, i.e. mangostin, the mangostin is taken as the maim active component and combined with the commonly-used filling agents in various pharmaceutical industries to be prepared into various dosage forms or as drugs, health care products, food additives and the like, and the mangostin can be internally and externally used for ulcerative stomatitis, pharyngitis and the like, and also can be used for preening and curing the oral diseases, for example, the benign and malignant tumors of oral cavity. The content of the mangostin is between 1.2 and 99.8 percent, can be separately used or used by matching other substances, and also can be used for preventing and curing the oral diseases of animals. The product overcomes the defects in the prior drug for curing the oral diseases, such as poor effect, irritability, high recurrence rate, side-effect and the like, and is the efficient and broad-spectrum new drug with anti-inflammation, rapid abirritation, non-toxicity, no side-effect and enhanced immunity.

The invention relates to a method for extracting and purifying neutral pseudo-ginseng polysaccharide, a research and an application for pharmacological activity for promoting cell proliferation. The pseudo-ginseng waste residue of the notoginsenoside extracted in the production process is taken as a raw material, a water extract and alcohol precipitation method is adopted for acquiring crude pseudo-ginseng polysaccharide and the DEAE Sepharose Fast Flow anion exchange chromatography is adopted for purifying the crude pseudo-ginseng polysaccharide so as to acquire five components: neutral pseudo-ginseng polysaccharide PNPS I and acidic pseudo-ginseng polysaccharide PNPS II, PNPS III, PNPS IV and PNPS V five samples. The research on the influence of the pseudo-ginseng polysaccharide on human periodontal ligament stem cell, mice osteoblast and human skin epidermis cell in vitro proliferation proves that the neutral pseudo-ginseng polysaccharide PNPS I is effective in boosting the periodontal ligament stem cell, mice osteoblast and human skin epidermis cell in vitro proliferation and the neutral pseudo-ginseng polysaccharide PNPS I can be used as an important drug intermediate for developing a new drug and a natural raw material for a functional healthcare food and also can be used as an active raw material of the household chemicals.

The present invention discloses a diverse chiral amino boric acid, a preparation method and an application thereof, wherein the diverse chiral amino boric acid is a compound represented by a formula (I) or a formula (II). The diverse chiral amino boric acid has the following characteristics that: the library containing rich compounds with the type is provided for researches on new drugs, a yield and stereoselectivity can be increased, the preparation cost of the class 2 drugs can be reduced, the synthesis route of the class 2 drugs can be simplified, and good economic benefits are provided.

The invention discloses a PCR (Polymerase Chain Reaction) primer, a PCR primer group, a PCR detection probe and a PCR detection kit for detecting hepatitis B virus as well as a detection method. The kit contains the high-sensitivity detection primer group and the high-sensitivity detection probe and can be used for detecting single copy HBVDNA (Hepatitis B virus-Deoxyribonucleic acid), the limit of detection of the kit in a serum specimen can reach 2IU/mL, and compared with an imported reagent Roche COBAS, the kit is relatively sensitive. The detection method disclosed by the invention can be used for detecting different subtypes of hepatitis B pathogens around the world; due to addition of an internal control system in the detection method, false negative can be effectively prevented; due to addition of a UNG (uracil-N-glycosylase) system in the detection method, pollution can be effectively avoided; the kit and the detection method have the beneficial effects that the kit and the detection method can be applied to diagnosis of hepatitis B, evaluation of research, development and screening of anti-hepatitis-B new drugs and evaluation of an anti-hepatitis-B treatment effect and relapsing and have wide clinical application effects, and the popularization and application of the kit and the detection method are facilitated.The invention discloses a PCR (Polymerase Chain Reaction) primer, a PCR primer group, a PCR detection probe and a PCR detection kit for detecting hepatitis B virus as well as a detection method. The kit contains the high-sensitivity detection primer group and the high-sensitivity detection probe and can be used for detecting single copy HBV DNA (Hepatitis B virus-Deoxyribonucleic acid), the limit of detection of the kit in a serum specimen can reach 2IU/mL, and compared with an imported reagent Roche COBAS, the kit is relatively sensitive. The detection method disclosed by the invention can be used for detecting different subtypes of hepatitis B pathogens around the world; due to addition of an internal control system in the detection method, false negative can be effectively prevented; due to addition of a UNG (uracil-N-glycosylase) system in the detection method, pollution can be effectively avoided; the kit and the detection method have the beneficial effects that the kit and the detection method can be applied to diagnosis of hepatitis B, evaluation of research, development and screening of anti-hepatitis-B new drugs and evaluation of an anti-hepatitis-B treatment effect and relapsing and have wide clinical application effects, and the popularization and application of the kit and the detection method are facilitated.